GSA Capital Partners’s IGC Pharma IGC Stock Holding History

GSA Capital Partners’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,821	Closed	-$12K	–	1856
2025 Q3	$12K	Buy	+27,821	New	+$10.6K	﹤0.01%	1592

Other funds holding IGC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

GSA Capital Partners's IGC Position: Q4 2025 in Review

GSA Capital Partners sold out of IGC Pharma (IGC) in Q4 2025, closing a stake of 27,821 shares — an estimated $12K sold.

GSA Capital Partners first reported a position in IGC in Q3 2025 and held it in 1 quarter. The position peaked at $12K in Q3 2025. 30 funds tracked by Wall St. Rank hold IGC as of Q4 2025.

GSA Capital Partners reported no remaining IGC Pharma position as of Q4 2025 after selling out during the quarter.
GSA Capital Partners sold 27,821 IGC Pharma shares in Q4 2025, an estimated $12K.
GSA Capital Partners first reported a position in IGC Pharma in Q3 2025 and held it in 1 quarter.
GSA Capital Partners's IGC Pharma position peaked at $12K in Q3 2025.
30 funds tracked by Wall St. Rank held IGC Pharma as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.